Levetiracetam Tablet, For Suspension
Product Images NDC 66993-100

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 66993-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Recommended Dosage Adjustment Formula (Levetiracetam 1)

A formula describing creatinine clearance (CLcr) calculation based on patient's age, weight, serum creatinine, and sex, showing adjustment for female patients by multiplying by 0.85. This text panel appears to be part of pharmacokinetic or dosing information related to Levetiracetam tablets for suspension.*

FDA Label Image

Figure 3 (Levetiracetam 10)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (Levetiracetam 11)

A vertical bar chart comparing the percentage of patients for Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%. The Levetiracetam group has a higher percentage (44.6%) compared to the Placebo group (19.6%).*

FDA Label Image

Figure 5 (Levetiracetam 12)

A vertical bar chart comparing the percentage of patients between placebo and levetiracetam groups. The x-axis shows two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis indicates the percentage of patients from 0% to 100%. The placebo group has about 45.2% patients, whereas the levetiracetam group shows about 72.2%, with an asterisk marking the levetiracetam bar.*

FDA Label Image

Imprint Marking (Levetiracetam 13)

Levetiracetam 250 mg/1 mL oral tablet for suspension bottle label by Prasco Laboratories. The white and orange label includes product and dosage information with barcode and regulatory details. The bottle has an orange cap and is intended for human prescription use.*

FDA Label Image

Carton 250 (Levetiracetam 14)

Levetiracetam 250 mg tablets for oral suspension carton distributed by Prasco Laboratories. The label indicates 6 tablets (6 tablets per blister card x 1 card), with administration instructions and a note that the tablets disintegrate in the mouth when taken with a sip of liquid. It is marked for institutional use only and includes storage information and directions to dispense a medication guide.*

FDA Label Image

Recommended Dosage Adjustment Formula (Levetiracetam 2)

A chemical structure diagram illustrating the molecular components of levetiracetam, the active ingredient in Levetiracetam tablets for suspension by Prasco Laboratories.*

FDA Label Image

Imprint Marking (Levetiracetam 3)

Levetiracetam 250 mg/1 tablet for suspension oral medication carton. The packaging is predominantly white with blue accents and contains various text blocks including brand and generic names, strength, dosage form, and Prasco Laboratories as the labeler. The product is intended for human prescription use.*

FDA Label Image

Imprint Marking (Levetiracetam 4)

Levetiracetam 500 mg/5 mL oral suspension bottle label from Prasco Laboratories. The label shows dosage form as tablet for suspension with active ingredient levetiracetam. It includes drug and labeler names prominently on the white and orange container label.*

FDA Label Image

Imprint Marking (Levetiracetam 5)

Levetiracetam 250 mg/1 oral tablet for suspension, packaged by Prasco Laboratories. The packaging shows a foil blister strip containing five tablets, each round and pale yellow in color, marked with the strength "250 mg".*

FDA Label Image

Imprint Marking (Levetiracetam 6)

Levetiracetam 250 mg/1 oral tablet for suspension bottle label. The white and orange rectangular label displays the product name, strength, and dosage form prominently. It indicates the labeler as Prasco Laboratories and includes standard drug labeling information such as barcodes and lot numbers on the lower half.*

FDA Label Image

Chemical Structure (Levetiracetam 7)

Chemical structure of levetiracetam, the active ingredient in the product Levetiracetam. The diagram shows the molecular arrangement including a pyrrolidone ring and side chains characteristic of this anticonvulsant drug.*

FDA Label Image

Figure 1 (Levetiracetam 8)

A bar chart depicting the percentage of patients by treatment group for Levetiracetam oral tablets for suspension. The x-axis shows placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups with respective sample sizes. The y-axis shows the percentage of patients, ranging from 0% to 45%. Bars indicate approximately 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day groups.*

FDA Label Image

Figure 2 (Levetiracetam 9)

A bar graph showing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis shows treatment groups with sample sizes, while the y-axis measures the percentage of patients from 0% to 45%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.